CancerWorld shared a post on LinkedIn:
“25 years ago, a breakthrough changed the future of Chronic Myeloid Leukemia (CML).
The arrival of tyrosine kinase inhibitors (TKIs) transformed a once life-limiting diagnosis into a disease many people could live with, manage, and even overcome.
But science alone was never enough.
The real story of CML is also about access, equity, persistence, and the global effort to ensure that lifesaving innovation reaches every patient, everywhere.
In the new CancerWorld | The Max Foundation Special Issue 2026 leading clinicians, researchers, advocates, and patients reflect on one of oncology’s most extraordinary revolutions and the responsibility that comes with it.
This special issue is not only about medical progress. It is about lives reclaimed, futures rebuilt, and the partnerships that turned discovery into hope for thousands around the world.
Because the true success of innovation is measured not only by what medicine can achieve , but by who it reaches.
Explore the stories, progress, and ongoing challenges shaping the future of CML care.”
More posts about CancerWorld.